Subscribe To
Moderna cancer vaccine with Merck’s Keytruda delays return of deadly skin cancer
By Julie Steenhuysen and Michael Erman (Reuters) – An experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co’s blockbuster immunotherapy Keytruda cut the risk of death or recurrence of the most deadly skin cancer by 44% compared Keytruda alone, U.S. researchers reported at The post Moderna cancer vaccine with Merck’s Keytruda delays return of deadly skin cancer appeared first on ForexTV...
Read More
Posted: Apr 16 2023, 15:19
Author Name: forextv
Views: 082064